Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1955 3
1956 1
1957 2
1958 4
1959 1
1960 6
1961 3
1962 8
1963 12
1964 25
1965 8
1966 8
1967 18
1968 12
1969 12
1970 22
1971 25
1972 35
1973 45
1974 66
1975 76
1976 69
1977 68
1978 68
1979 70
1980 94
1981 119
1982 128
1983 116
1984 144
1985 145
1986 131
1987 140
1988 108
1989 119
1990 147
1991 118
1992 121
1993 93
1994 90
1995 93
1996 76
1997 68
1998 70
1999 78
2000 61
2001 87
2002 64
2003 93
2004 90
2005 76
2006 76
2007 64
2008 69
2009 69
2010 83
2011 75
2012 71
2013 88
2014 74
2015 52
2016 65
2017 87
2018 93
2019 76
2020 75
2021 78
2022 69
2023 64
2024 55
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,526 results

Results by year

Filters applied: . Clear all
Page 1
[Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].
Hou YJ, Zhao L, Liu XX, Ma YY. Hou YJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):622-6. doi: 10.7534/j.issn.1009-2137.2016.02.059. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016. PMID: 27151041 Review. Chinese.
It has long been recognized that thiopurines are critical components in the treatment for prevention of recurrence in childhood ALL, the 6-mercaptopurine (6-MP) has usually been used in daily long-term maintenance therapy, and 6-thioguanine (6-TG) limited to the reinforcem …
It has long been recognized that thiopurines are critical components in the treatment for prevention of recurrence in childhood ALL, the 6-m …
A well-tolerated and rapidly acting thiopurine for IBD?
Florin THJ, Wright JD, Jambhrunkar SD, Henman MG, Popat A. Florin THJ, et al. Drug Discov Today. 2019 Jan;24(1):37-41. doi: 10.1016/j.drudis.2018.09.001. Epub 2018 Sep 7. Drug Discov Today. 2019. PMID: 30196006 Review.
TPMT Polymorphism: When Shield Becomes Weakness.
Katara P, Kuntal H. Katara P, et al. Interdiscip Sci. 2016 Jun;8(2):150-155. doi: 10.1007/s12539-015-0111-1. Epub 2015 Aug 22. Interdiscip Sci. 2016. PMID: 26297310 Review.
TPMT is one of the important metabolic enzymes of phase II metabolic pathway and catalyzes methylation of thiopurine drugs such as azathioprine, 6-thioguanine and 6-mercaptopurine, which are used to treat patients with neoplasia and autoimmune disease as well as transplant …
TPMT is one of the important metabolic enzymes of phase II metabolic pathway and catalyzes methylation of thiopurine drugs such as azathiopr …
Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide.
Crouwel F, Simsek M, Mulder CJ, Buiter HJ, De Boer NK. Crouwel F, et al. J Gastrointestin Liver Dis. 2020 Dec 13;29(4):637-645. doi: 10.15403/jgld-2765. J Gastrointestin Liver Dis. 2020. PMID: 33331335 Free article. Review.
In this review we will provide practical information on initiating and maintaining thioguanine therapy in IBD and provide information concerning safety issues and future perspectives. The thioguanine toxicity profile is relatively mild and the reported incidence of …
In this review we will provide practical information on initiating and maintaining thioguanine therapy in IBD and provide information …
The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review.
Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, De Boer NK. Bayoumy AB, et al. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):111-123. doi: 10.1080/17425255.2020.1719996. Epub 2020 Feb 24. Expert Opin Drug Metab Toxicol. 2020. PMID: 32090622 Free article. Review.
Introduction: In the 1950s, thioguanine (TG), a thiopurine-derivative together with azathioprine (AZA) and mercaptopurine (MP), were developed for the treatment of childhood leukemia. ...Thioguanine toxicity, especially myelotoxicity, and hepatotoxicity, including n …
Introduction: In the 1950s, thioguanine (TG), a thiopurine-derivative together with azathioprine (AZA) and mercaptopurine (MP), were …
Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
de Boer NKH, Simsek M, Meijer B, Neurath MF, van Bodegraven A, Mulder CJJ. de Boer NKH, et al. Gut. 2023 Oct;72(10):1985-1991. doi: 10.1136/gutjnl-2023-329679. Epub 2023 Jun 28. Gut. 2023. PMID: 37380330 Review.
One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. ...
One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with infl …
Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.
Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Meijer B, et al. World J Gastroenterol. 2016 Oct 28;22(40):9012-9021. doi: 10.3748/wjg.v22.i40.9012. World J Gastroenterol. 2016. PMID: 27833392 Free PMC article. Review.
AIM: To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease (IBD) patients, irrespective of the (hepato-) toxicity profile. METHODS: A systematic literature search of the MEDLINE database using PubMed was …
AIM: To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease (IBD …
Thioguanine-induced symptomatic thrombocytopenia.
Wenzl HH, Högenauer C, Fickert P, Petritsch W. Wenzl HH, et al. Am J Gastroenterol. 2004 Jun;99(6):1195. doi: 10.1111/j.1572-0241.2004.30292.x. Am J Gastroenterol. 2004. PMID: 15180747 No abstract available.
The future of thiopurine pharmacogenomics.
Duley JA, Somogyi AA, Martin JH. Duley JA, et al. Pharmacogenomics. 2012 Nov;13(14):1549-52. doi: 10.2217/pgs.12.140. Pharmacogenomics. 2012. PMID: 23148628 No abstract available.
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF. de Boer NKH, et al. J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181. J Crohns Colitis. 2018. PMID: 29293971 Review.
Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free remission in patients with inflammatory bowel disease. ...
Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corti …
4,526 results